Atrial Fibrillation in Beta-Thalassemia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

350 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-09-01

Study Completion Date

2032-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study aims to evaluate the clinical, laboratory and instrumental differences that exist between beta-thalassemia patients with atrial fibrillation and those not affected by arrhythmia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

T2* in Transfusion Dependant Anemia, MI, LVF, Normal Patients

NCT00520559

Thalassemia

COMPLETED

Assessment of Cognitive Function, Fatigue and Health Related Quality of Life in Children With Beta Thalassemia

NCT05469230

Cognitive Change Beta-Thalassemia Fatigue +1 more

COMPLETED

Effect of Deferasirox on Patients With Cardiac MRI T2* < 20 Msec

NCT00879242

Beta Thalassemia Transfusion Dependent

COMPLETED PHASE2

Detection Of β-thalassemia Carriers In Assiut

NCT03822585

Beta-Thalassemia

UNKNOWN NA

A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis

NCT00171171

Beta-Thalassemia Hemosiderosis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Observational, retrospective and prospective, single-center study, which involves the collection of clinical, laboratory, electrocardiographic and imaging data of patients with major or intermediate thalassemia who have performed, from 2012 to 2022, or will perform in the next 10 years, a cardiological evaluation at the Cardiology Unit of the University Hospital of Ferrara. Patients will be divided into two groups: thalassemia patients with atrial fibrillation (paroxysmal, persistent or permanent) and thalassemia patients with no history of atrial fibrillation.

The objective of the study is to evaluate whether there is a different prevalence of the characteristics analyzed among these patient populations.

As secondary outcome, the effect of SGLT2-inhibitors (empaglifozin, dapaglifozin, ...) will be evaluated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation Thalassemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Beta-thalassemia

Patients with Beta-thalassemia undergoing a cardiological evaluation

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Transfusion-dependent Beta-thalassemia;
2. Follow-Up at the Cardiology Unit of the University Hospital of Ferrara;
3. Electrocardiogram performed;
4. Echocardiogram performed.